Walleye Capital
ARCT icon

Walleye Capital’s Arcturus Therapeutics ARCT Stock Holding History

Walleye Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.9K Buy
+11,300
New +$89.1K ﹤0.01% 4029
2026
Q1 		– Sell
-11,200
Closed -$68.7K – 4354
2025
Q4 		$68.7K Sell
11,200
-6,200
-36% -$67K ﹤0.01% 3998
2025
Q3 		$321K Buy
17,400
+1,200
+7% +$19.3K ﹤0.01% 2960
2025
Q2 		$211K Buy
+16,200
New +$192K ﹤0.01% 3322
2025
Q1 		– Sell
-100
Closed -$1.7K – 4224
2024
Q4 		$1.7K Buy
+100
New +$1.88K ﹤0.01% 4670
2024
Q3 		– Sell
-10,600
Closed -$258K – 5243
2024
Q2 		$258K Buy
10,600
+3,300
+45% +$100K ﹤0.01% 4104
2024
Q1 		$247K Buy
+7,300
New +$259K ﹤0.01% 3827

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Walleye Capital's ARCT Position: Q2 2026 in Review

Walleye Capital opened a new position in Arcturus Therapeutics (ARCT) in Q2 2026: 19,323 shares worth $130K. The stake represents ﹤0.01% of the portfolio and ranks #3742 among its holdings. This is a return to the name: Walleye Capital previously reported a position in ARCT as recently as Q4 2025.

Walleye Capital first reported a position in ARCT in Q1 2021 and has held it in 6 quarters since. The position peaked at $1.07M in Q2 2022. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Walleye Capital held 19,323 shares of Arcturus Therapeutics worth $130K as of Q2 2026.
  • Arcturus Therapeutics was a new Walleye Capital position in Q2 2026.
  • Arcturus Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3742 holding.
  • Walleye Capital first reported a position in Arcturus Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • Walleye Capital's Arcturus Therapeutics position peaked at $1.07M in Q2 2022.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.